ZA914185B - Method for treating alcoholism with nalmefene - Google Patents

Method for treating alcoholism with nalmefene

Info

Publication number
ZA914185B
ZA914185B ZA914185A ZA914185A ZA914185B ZA 914185 B ZA914185 B ZA 914185B ZA 914185 A ZA914185 A ZA 914185A ZA 914185 A ZA914185 A ZA 914185A ZA 914185 B ZA914185 B ZA 914185B
Authority
ZA
South Africa
Prior art keywords
nalmefene
treating alcoholism
alcoholism
treating
alcoholics
Prior art date
Application number
ZA914185A
Other languages
English (en)
Inventor
John David Sinclair
David Sinclair John
Harry Scheinin
Scheinin Harry
Risto Lammintausta
Lammintausta Risto
Original Assignee
David Sinclair John
Scheinin Harry
Lammintausta Risto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by David Sinclair John, Scheinin Harry, Lammintausta Risto filed Critical David Sinclair John
Publication of ZA914185B publication Critical patent/ZA914185B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
ZA914185A 1990-06-04 1991-06-03 Method for treating alcoholism with nalmefene ZA914185B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/532,424 US5086058A (en) 1990-06-04 1990-06-04 Method for treating alcoholism with nalmefene

Publications (1)

Publication Number Publication Date
ZA914185B true ZA914185B (en) 1992-07-29

Family

ID=24121726

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA914185A ZA914185B (en) 1990-06-04 1991-06-03 Method for treating alcoholism with nalmefene

Country Status (19)

Country Link
US (1) US5086058A (xx)
EP (1) EP0531415B1 (xx)
JP (1) JP3059213B2 (xx)
AT (1) ATE145329T1 (xx)
AU (1) AU642748B2 (xx)
CA (1) CA2084519C (xx)
DE (1) DE69123247T2 (xx)
DK (1) DK0531415T3 (xx)
ES (1) ES2097209T3 (xx)
FI (1) FI925513A0 (xx)
GR (1) GR3022289T3 (xx)
HU (1) HU210637B (xx)
IE (1) IE77333B1 (xx)
LT (1) LT3893B (xx)
LV (1) LV10190B (xx)
NZ (1) NZ238391A (xx)
RU (1) RU2090190C1 (xx)
WO (1) WO1991018605A1 (xx)
ZA (1) ZA914185B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US6271239B1 (en) * 1992-04-13 2001-08-07 Regents Of The University Of Minnesota Delta opioid receptor-selective benzylidene-substituted morphinans
US5352680A (en) * 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
USRE36547E (en) * 1992-09-21 2000-02-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298622A (en) * 1993-05-12 1994-03-29 Regents Of The University Of Minnesota Spiroindane opiate analogs
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
US5587381A (en) * 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
WO1997018781A1 (en) * 1995-11-20 1997-05-29 University Of Miami Method of treating nicotine dependence
US5878750A (en) * 1996-11-14 1999-03-09 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
JP2001526229A (ja) * 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド投薬剤形の乱用を防止する方法
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040024004A1 (en) * 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6528520B2 (en) * 2000-08-15 2003-03-04 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6846831B2 (en) 2000-08-15 2005-01-25 Cpd, Llc Method of treating the syndrome of lipodystrophy
CA2446550C (en) 2001-05-11 2012-03-06 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
JP4736323B2 (ja) * 2001-07-13 2011-07-27 アークレイ株式会社 分析用具を備えた濃度測定装置用の穿刺要素一体装着体、および体液採取用具
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
AU2002323032B2 (en) 2001-08-06 2005-02-24 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
WO2003013433A2 (en) * 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
US7501433B2 (en) * 2002-05-17 2009-03-10 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
SI2561860T1 (en) * 2002-05-31 2018-05-31 Titan Pharmaceuticals, Inc. An implantable polymeric device for prolonged release of buprenorphine
DK1551372T3 (en) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20050031667A1 (en) 2003-03-31 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
CA2522471A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8017622B2 (en) 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US20060009478A1 (en) * 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP2526932B1 (en) * 2006-06-19 2017-06-07 Alpharma Pharmaceuticals LLC Pharmaceutical composition
PT2724722T (pt) 2006-10-20 2017-03-14 Neurendo Pharma Llc Método de restaurar o efeito incretina
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
DK2291380T3 (da) * 2008-04-24 2011-12-05 Janssen Pharmaceutica Nv Nalmefen-prodrugs
DK2307420T3 (da) * 2008-04-24 2012-02-27 Janssen Pharmaceutica Nv Nalmefendiester-prodrugs
PE20110422A1 (es) * 2008-07-07 2011-07-01 Euro Celtique Sa Composicion farmaceutica que comprende antagonistas opioides
PT2405915T (pt) 2009-03-10 2019-01-29 Euro Celtique Sa Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
WO2014170353A1 (en) * 2013-04-17 2014-10-23 H. Lundbeck A/S Nalmefene for treatment of patients with sleep disorder
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN106456634A (zh) * 2014-04-22 2017-02-22 大塚制药株式会社 布雷帕唑和纳美芬的组合及其用于治疗物质有关的病症的用途
ES2787223T3 (es) 2014-11-07 2020-10-15 Univ Minnesota Sales y composiciones útiles para tratar enfermedades
WO2017184819A1 (en) * 2016-04-22 2017-10-26 Taiwanj Pharmaceuticals Co., Ltd. Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist

Also Published As

Publication number Publication date
ES2097209T3 (es) 1997-04-01
US5086058A (en) 1992-02-04
FI925513A (fi) 1992-12-04
HUT65523A (en) 1994-06-28
NZ238391A (en) 1997-06-24
LTIP1486A (en) 1995-09-25
DK0531415T3 (da) 1996-12-09
AU7974091A (en) 1991-12-31
IE911888A1 (en) 1991-12-04
HU9203835D0 (en) 1993-03-29
LT3893B (en) 1996-04-25
CA2084519C (en) 1999-02-09
AU642748B2 (en) 1993-10-28
HU210637B (en) 1995-06-28
WO1991018605A1 (en) 1991-12-12
EP0531415B1 (en) 1996-11-20
JP3059213B2 (ja) 2000-07-04
CA2084519A1 (en) 1991-12-05
EP0531415A1 (en) 1993-03-17
LV10190A (lv) 1994-10-20
DE69123247T2 (de) 1998-01-15
IE77333B1 (en) 1997-12-03
GR3022289T3 (en) 1997-04-30
JPH06506665A (ja) 1994-07-28
RU2090190C1 (ru) 1997-09-20
LV10190B (en) 1995-06-20
FI925513A0 (fi) 1992-12-04
ATE145329T1 (de) 1996-12-15
DE69123247D1 (de) 1997-01-02

Similar Documents

Publication Publication Date Title
GR3022289T3 (en) Method for treating alcoholism with nalmefene
RU92016403A (ru) Способ лечения алкоголизма налмефеном
MXPA99001239A (es) Proceso mejorado para la produccion de bebidas alcoholicas que utilizan semilla de malta.
EP0825196A3 (en) Enzyme-treated hesperidin, process for producing the same and method of using enzyme-treated hesperidin
AU3838097A (en) Process for the production of alcholic coffee drinks
ZA957645B (en) A method for production of ethyl alcohol
EP0629879A3 (de) Verfahren zum Bestimmen von Tiefenwerten eines Gewässers.
ZA9472B (en) Process for producing low molecular-weight poly-1-olefins.
GR3015586T3 (en) Process for producing fuel oil and gas by cracking waste rubber.
MY119686A (en) Sequential distillation process for removing tetrahydroazepine from aminocapronitrile and/or hexamethylenediamine
AU5102490A (en) Process of treating alcoholic beverages by vapor-arbitrated pervaporisation
ZA943254B (en) A process to increase the water vapour permeability of leather, especialy for application in the automobile industry.
HUT60202A (en) Method for producing cork stopper
AU3258993A (en) Method for producing BIS-pyridinic derivatives with acetylcholinesterase inhibiting properties
HUT75184A (en) Plastisol, process for producing thereof and uses thereof
GR3024442T3 (en) Method to purify streptolysin o, intact streptolysin o obtainable by this method and its use
AU7275994A (en) Process for producing emulsion fuel
HUT64765A (en) Method for producing oxa-bicyclo[2.2.1] heptane-2,3-dimethanol-derivatives
AU2767192A (en) Process for producing chloroisocyanurates with hypochlorous acid
NO950978D0 (no) Polyolefinbasert pigmentert blanding, samt fremgangsmåte for fremstilling av tilformede gjenstander med utgangspunkt i blandingen
EP0633263A3 (en) Process for the preparation of thiophene derivatives.
HU9400262D0 (en) Process for producing sparkling drinks
HU9400762D0 (en) Process for producing intermediate
HU9301383D0 (en) Method for producing drink concentrates
LV10483B (en) Process for producing sparkling wines